pubmed-article:18294280 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:18294280 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
pubmed-article:18294280 | lifeskim:mentions | umls-concept:C0302600 | lld:lifeskim |
pubmed-article:18294280 | lifeskim:mentions | umls-concept:C0023828 | lld:lifeskim |
pubmed-article:18294280 | lifeskim:mentions | umls-concept:C0758314 | lld:lifeskim |
pubmed-article:18294280 | pubmed:issue | 5 | lld:pubmed |
pubmed-article:18294280 | pubmed:dateCreated | 2008-4-2 | lld:pubmed |
pubmed-article:18294280 | pubmed:abstractText | Causing damage to angiogenic vessels is a promising approach for cancer chemotherapy. The present study is a codification of a designed liposomal drug delivery system (DDS) for antineovascular therapy (ANET) with 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC). The authors have previously reported that liposomalized 5'-O-dipalmitoylphosphatidyl CNDAC (DPP-CNDAC), a phospholipid derivative of the novel antitumor nucleoside CNDAC, is quite useful for ANET. DPP-CNDAC liposomes modified with APRPG, a peptide having affinity toward angiogenic vessels, efficiently suppressed tumor growth by damaging angiogenic endothelial cells. In the present study, the authors masked the hydrophilic moiety of DPP-CNDAC, namely, CNDAC, on the liposomal surface with APRPG-polyethyleneglycol (PEG) conjugate to improve the availability of DPP-CNDAC liposomes. The use of the APRPG-PEG conjugate attenuated the negative zeta-potential of the DPP-CNDAC liposomes and reduced the agglutinability of them in the presence of serum. These effects improved the blood level of DPP-CNDAC liposomes in colon 26 NL-17 tumor-bearing BALB/c male mice, resulting in enhanced accumulation of them in the tumor. Laser scanning microscopic observations indicated that APRPG-PEG-modified DPP-CNDAC liposomes (LipCNDAC/APRPG-PEG) colocalized with angiogenic vessels and strongly induced apoptosis of tumor cells, whereas PEG-modified DPP-CNDAC liposomes (LipCNDAC/PEG) did not. In fact, LipCNDAC/APRPG-PEG suppressed the tumor growth more strongly compared to LipCNDAC/PEG and increased significantly the life span of the mice. The present study is a good example of an effective liposomal DDS for ANET that is characterized by: (i) phospholipid derivatization of a certain anticancer drug to suit the liposomal formulation; (ii) PEG-shielding for masking undesirable properties of the drug on the liposomal surface; and (iii) active targeting to angiogenic endothelial cells using a specific probe. | lld:pubmed |
pubmed-article:18294280 | pubmed:language | eng | lld:pubmed |
pubmed-article:18294280 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18294280 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:18294280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18294280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18294280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18294280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18294280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18294280 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:18294280 | pubmed:month | May | lld:pubmed |
pubmed-article:18294280 | pubmed:issn | 1349-7006 | lld:pubmed |
pubmed-article:18294280 | pubmed:author | pubmed-author:AsaiTomohiroT | lld:pubmed |
pubmed-article:18294280 | pubmed:author | pubmed-author:OkuNaotoN | lld:pubmed |
pubmed-article:18294280 | pubmed:author | pubmed-author:ShutoSatoshiS | lld:pubmed |
pubmed-article:18294280 | pubmed:author | pubmed-author:ShimizuKosuke... | lld:pubmed |
pubmed-article:18294280 | pubmed:author | pubmed-author:KatanasakaYas... | lld:pubmed |
pubmed-article:18294280 | pubmed:author | pubmed-author:MaedaNoriyuki... | lld:pubmed |
pubmed-article:18294280 | pubmed:author | pubmed-author:MiyazawaSouic... | lld:pubmed |
pubmed-article:18294280 | pubmed:author | pubmed-author:HatanakaKenta... | lld:pubmed |
pubmed-article:18294280 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:18294280 | pubmed:volume | 99 | lld:pubmed |
pubmed-article:18294280 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:18294280 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:18294280 | pubmed:pagination | 1029-33 | lld:pubmed |
pubmed-article:18294280 | pubmed:meshHeading | pubmed-meshheading:18294280... | lld:pubmed |
pubmed-article:18294280 | pubmed:meshHeading | pubmed-meshheading:18294280... | lld:pubmed |
pubmed-article:18294280 | pubmed:meshHeading | pubmed-meshheading:18294280... | lld:pubmed |
pubmed-article:18294280 | pubmed:meshHeading | pubmed-meshheading:18294280... | lld:pubmed |
pubmed-article:18294280 | pubmed:meshHeading | pubmed-meshheading:18294280... | lld:pubmed |
pubmed-article:18294280 | pubmed:meshHeading | pubmed-meshheading:18294280... | lld:pubmed |
pubmed-article:18294280 | pubmed:meshHeading | pubmed-meshheading:18294280... | lld:pubmed |
pubmed-article:18294280 | pubmed:meshHeading | pubmed-meshheading:18294280... | lld:pubmed |
pubmed-article:18294280 | pubmed:meshHeading | pubmed-meshheading:18294280... | lld:pubmed |
pubmed-article:18294280 | pubmed:meshHeading | pubmed-meshheading:18294280... | lld:pubmed |
pubmed-article:18294280 | pubmed:meshHeading | pubmed-meshheading:18294280... | lld:pubmed |
pubmed-article:18294280 | pubmed:meshHeading | pubmed-meshheading:18294280... | lld:pubmed |
pubmed-article:18294280 | pubmed:meshHeading | pubmed-meshheading:18294280... | lld:pubmed |
pubmed-article:18294280 | pubmed:year | 2008 | lld:pubmed |
pubmed-article:18294280 | pubmed:articleTitle | Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC. | lld:pubmed |
pubmed-article:18294280 | pubmed:affiliation | Department of Medical Biochemistry and Global COE, University of Shizuoka School of Pharmaceutical Sciences, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan. | lld:pubmed |
pubmed-article:18294280 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:18294280 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |